This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: August 15, 2005
Last updated: November 16, 2011
Last verified: November 2011
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.

Condition Intervention Phase
Diabetic Retinopathy Drug: Octreotide Acetate in Microspheres Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • time to progression of diabetic retinopathy

Secondary Outcome Measures:
  • time to development or progression of macular edema,
  • time to moderate vision loss

Enrollment: 312
Study Start Date: February 2000
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Octreotide Acetate in Microspheres Drug: Octreotide Acetate in Microspheres
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females with type 1 and type 2 diabetes mellitus
  • Moderately severe or severe NPDR or mild PDR in at least one eye:

    • with an Early Treatment Diabetic Retinopathy Study (ETDRS) visual score of > 35 letters; and
    • not previously treated with scatter photocoagulation.
  • HbA1c < 13% at study entry

Exclusion Criteria:

  • Condition which could interfere with the assessment of retinopathy progression
  • History of symptomatic gallstones without cholecystectomy
  • Brittle diabetes or history of severe hypoglycemia unawareness
  • Previous treatment with a somatostatin analogue
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00130845

United States, New Jersey
East Hanover, New Jersey, United States, 07936
Sponsors and Collaborators
Study Chair: Customer Information Novartis
  More Information

Responsible Party: Novartis Identifier: NCT00130845     History of Changes
Other Study ID Numbers: CSMS995 0804
Study First Received: August 15, 2005
Last Updated: November 16, 2011

Keywords provided by Novartis:
Diabetic retinopathy, Octreotide Acetate in Microspheres

Additional relevant MeSH terms:
Diabetic Retinopathy
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on September 19, 2017